Integra LifeSciences Holdings Corporation
NASDAQ•IART
CEO: Dr. Stuart M. Essig Ph.D.
セクター: Healthcare
業種: Medical - Devices
上場日: 1995-08-16
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
連絡先情報
時価総額
$720.14M
PER (TTM)
-1.4
26.6
配当利回り
--
52週高値
$23.27
52週安値
$8.91
52週レンジ
順位46Top 59.5%
3.5
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 3.5 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$434.93M+0.00%
直近4四半期の推移
EPS
-$0.02+0.00%
直近4四半期の推移
フリーCF
-$37.25M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Revenue Growth Despite Issues Total revenue reached $1.64B, up 1.5% for 2025, primarily driven by Acclarent sales integration despite quality issues.
Strategic Acquisition Integration Completed Acclarent ENT portfolio acquisition in Q2 2024, enhancing Codman Specialty Surgical segment positioning globally.
Durepair Rights Secured Secured Durepair dura substitute rights in October 2024 for $45.0M cash consideration, bolstering TT segment.
Strong Year-End Liquidity Year-end cash and equivalents totaled $235.0M, supported by strong liquidity management across foreign operations.
リスク要因
Major Goodwill Impairment Reported net loss of $(516.5)M, heavily impacted by $511.4M goodwill impairment charge recorded in Q2 2025.
Gross Margin Contraction Gross margin decreased to 50.9% from 54.8% due to quality issues, higher costs, and tariff impacts across segments.
FDA Regulatory Scrutiny Multiple FDA warning letters received for quality systems; remediation efforts ongoing, potentially disrupting production timelines.
Macroeconomic Uncertainty Risks Continuing global macroeconomic uncertainty, tariffs, and geopolitical instability pose risks to demand and supply chain stability.
見通し
Braintree Facility Operationalization Plan to operationalize new Braintree manufacturing facility by first half of 2026 to consolidate production efforts effectively.
DuraSorb PMA Approval Anticipate securing PMA approval for DuraSorb in 2026 for implant-based breast reconstruction indications.
Restructuring for Resilience Approved restructuring initiative expecting $12.6M aggregate costs through 2026 to improve supply chain resilience.
Executive Severance Plan Executive Severance Pay Plan adopted in February 2026 to support talent retention and leadership continuity efforts.
同業比較
売上高 (TTM)
$2.84B
$1.64B
$1.37B
粗利益率 (最新四半期)
78.3%
70.5%
70.0%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| PRAX | $6.21B | -21.8 | -58.7% | 0.0% |
| ESTA | $1.86B | -36.7 | -201.8% | 74.0% |
| TNDM | $1.48B | -7.2 | -142.0% | 64.0% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
4.4%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい
深度リサーチ
次回決算:2026年4月29日
EPS:$0.40
|売上高:$381.81M
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし